Vascular targeted therapies in oncology

Neovascularization is intimately involved in tumor survival, progression, and spread, factors known to contribute significantly to treatment failures. Thus, strategies targeting the tumor blood vessel support network may offer not only unique therapeutic opportunities in their own right, but also novel means of enhancing the efficacies of conventional anticancer treatments. This article reviews one such therapeutic approach directed at the tumor blood vessel support network. Vascular disrupting therapies seek the destruction of the established neovasculature of actively growing tumors. The goal of these therapies is to cause a rapid and catastrophic shutdown in the vascular function of the tumor in order to arrest the blood flow and produce tumor cell death as a result of oxygen and nutrient deprivation and the build up of waste products.

[1]  A. Rojiani,et al.  Preclinical Evaluations of Therapies Combining the Vascular Targeting Agent Combretastatin A-4 Disodium Phosphate and Conventional Anticancer Therapies in the Treatment of Kaposi's Sarcoma , 2002, Acta oncologica.

[2]  B. Baguley,et al.  DMXAA: an antivascular agent with multiple host responses. , 2002, International journal of radiation oncology, biology, physics.

[3]  P. LoRusso,et al.  Differentiation and definition of vascular-targeted therapies. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  F. Westwood,et al.  Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M. Ravic,et al.  5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent , 2006, Clinical Cancer Research.

[6]  D. Chaplin,et al.  An update on the clinical development of drugs to disable tumor vasculature , 2007, Expert opinion on drug discovery.

[7]  M. Bibby,et al.  In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug , 1999, British Journal of Cancer.

[8]  J. Lewin,et al.  A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. , 2002, Cancer research.

[9]  P. Thorpe.  Vascular Targeting Agents as Cancer Therapeutics , 2004, Clinical Cancer Research.

[10]  M. Horsman,et al.  Vascular‐targeting therapies for treatment of malignant disease , 2004, Cancer.

[11]  Logtenberg,et al.  New strategies in anti‐vascular cancer therapy , 1999, European journal of clinical investigation.

[12]  I. Tannock.  Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. , 1970, Cancer research.

[13]  M. Horsman,et al.  Current development status of small-molecule vascular disrupting agents. , 2006, Current opinion in investigational drugs.

[14]  A. Rojiani,et al.  Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy , 2002, International journal of cancer.

[15]  A. Rojiani,et al.  Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. , 2002, International journal of radiation oncology, biology, physics.

[16]  W. Wilson,et al.  Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. , 1998, International journal of radiation oncology, biology, physics.

[17]  D. Siemann,et al.  Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor Vascularity , 2006, Clinical Cancer Research.

[18]  J. Folkman,et al.  How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. , 1986, Cancer research.

[19]  E. Ruoslahti.  Specialization of tumour vasculature , 2002, Nature Reviews Cancer.

[20]  L. Ellis,et al.  Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. , 2000, The oncologist.

[21]  D. Blakey,et al.  ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. , 2002, Cancer research.

[22]  W. Shi,et al.  Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. , 2004, International journal of radiation oncology, biology, physics.

[23]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[24]  W. Shi,et al.  Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. , 2003, Seminars in radiation oncology.

[25]  M. Horsman,et al.  Small-Molecule Vascular Disrupting Agents in Cancer Therapy , 2008 .

[26]  Christian Streffer,et al.  Morphological Aspects of Tumor Angiogenesis and Microcirculation , 2000 .

[27]  L. Ellis,et al.  Overview of angiogenesis: Biologic implications for antiangiogenic therapy. , 2001, Seminars in oncology.

[28]  M. Horsman,et al.  Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. , 2006, Cancer research.

[29]  D. Chaplin,et al.  Tumour vasculature as a target for cancer therapy. , 1999, British journal of cancer.

[30]  Peter Vaupel,et al.  Blood Perfusion and Microenvironment of Human Tumors , 2000 .

[31]  Dietmar W. Siemann.  Vascular targeting agents , 2002 .

[32]  M. Hendrix,et al.  Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma , 2003, Nature Reviews Cancer.

[33]  Chryso Kanthou,et al.  Disrupting tumour blood vessels , 2005, Nature Reviews Cancer.

[34]  F. Lee,et al.  Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. , 2001, Anticancer research.

[35]  M. Stratford,et al.  Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[36]  J. Overgaard,et al.  Improved Tumor Response by Combining Radiation and the Vascular-Damaging Drug 5,6-Dimethylxanthenone-4-acetic Acid , 2001, Radiation research.

[37]  J. Folkman,et al.  Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. , 1977, Microvascular research.

[38]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[39]  J. Overgaard,et al.  Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  D. Siemann.  Therapeutic strategies that selectively target and disrupt established tumor vasculature. , 2004, Hematology/oncology clinics of North America.

[41]  Oswald Wagner,et al.  Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. , 2004, The New England journal of medicine.

[42]  M A Konerding,et al.  Microvascular corrosion casting in the study of tumor vascularity: a review. , 1995, Scanning microscopy.

[43]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[44]  P. Lambin,et al.  In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. , 2001, International journal of radiation oncology, biology, physics.

[45]  S. Rafii,et al.  Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. , 2005, The Journal of clinical investigation.

[46]  R. Kerbel,et al.  On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.